-
1
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
-
2
-
-
84879198467
-
Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: Results from QUEST-1, a phase III trial
-
[abstract 1425]
-
Jacobson I, Dore GJ, Foster GR, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S574 [abstract 1425].
-
(2013)
J Hepatol
, vol.58
, pp. S574
-
-
Jacobson, I.1
Dore, G.J.2
Foster, G.R.3
-
3
-
-
84879198467
-
Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: Results from QUEST-2, a phase III trial
-
[abstract 1413]
-
Manns M, Marcellin P, Fred Poordad FP, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S568 [abstract 1413].
-
(2013)
J Hepatol
, vol.58
, pp. S568
-
-
Manns, M.1
Marcellin, P.2
Fred Poordad, F.P.3
-
4
-
-
84884223989
-
Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study
-
[abstract 1418]
-
Dore GJ, Lawitz E, Hézode C, et al,. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013; 58 (Suppl. 1): S570-S571 [abstract 1418].
-
(2013)
J Hepatol
, vol.58
, pp. S570-S571
-
-
Dore, G.J.1
Lawitz, E.2
Hézode, C.3
-
5
-
-
84932619401
-
Randomized study of daclatasvir plus peginterferon alfa-2a and ribavirin for previously untreated chronic hepatitis C
-
Jul 30. [Epub ahead of print] PMID: 25080450
-
Hezode C, Hirschfield G, Ghesquiere W, et al,. Randomized study of daclatasvir plus peginterferon alfa-2a and ribavirin for previously untreated chronic hepatitis C. Gut 2014; Jul 30. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print] PMID: 25080450
-
(2014)
Gut
-
-
Hezode, C.1
Hirschfield, G.2
Ghesquiere, W.3
-
6
-
-
84892761633
-
COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders
-
March 3-6, 2013: Atlanta, GA [Abstract 155LB]
-
Lawitz E, Ghalib R, Rodriguez-Torres M,. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013: Atlanta, GA [Abstract 155LB].
-
20th Conference on Retroviruses and Opportunistic Infections
-
-
Lawitz, E.1
Ghalib, R.2
Rodriguez-Torres, M.3
-
7
-
-
84898470261
-
-
American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. (accessed 20 October 2014)
-
American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C, 2014. Available at: http://www.hcvguidelines.org/full-report-view (accessed 20 October 2014).
-
(2014)
Recommendations for Testing, Managing, and Treating Hepatitis C
-
-
-
8
-
-
85116185033
-
-
™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection May 16, 2014. (accessed 20 October 2014)
-
™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection. May 16, 2014. Available at: https://www.jnj.com/news/all/OLYSIO-simeprevir-receives-marketing-authorisation-in-the-European-Union-for-the-treatment-of-adults-with-hepatitis-C-genotype-1-and-4-infection (accessed 20 October 2014).
-
Janssen-Cilag International
-
-
-
10
-
-
85116185044
-
-
® (asunaprevir) dual regimen Bristol-Myers Squibb. July 7, 2014. (accessed 20 October 2014)
-
® (asunaprevir) dual regimen. July 7, 2014. Available at: http://news.bms.com/press-release/japan-approves-first-all-oral-interferon-and-ribavirin-free-hepatitis-c-treatment-dakl (accessed 20 October 2014).
-
-
-
-
11
-
-
84901274668
-
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase
-
Lemm JA, Liu M, Gentles RG, et al,. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2014; 58: 3485-3495.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 3485-3495
-
-
Lemm, J.A.1
Liu, M.2
Gentles, R.G.3
-
12
-
-
84901289997
-
A randomized, placebo-controlled, single ascending dose study of BMS-791325, a hepatitis C virus NS5B polymerase inhibitor, in genotype 1 infection
-
Karen S, Lemm J, Eley T, et al,. A randomized, placebo-controlled, single ascending dose study of BMS-791325, a hepatitis C virus NS5B polymerase inhibitor, in genotype 1 infection. Antimicrob Agents Chemother 2014; 58: 3496-3503.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 3496-3503
-
-
Karen, S.1
Lemm, J.2
Eley, T.3
-
13
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
-
14
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
15
-
-
84865494240
-
Factors that predict response of patients with hepatitis C virus infection to boceprevir
-
Poordad F, Bronowicki JP, Gordon SC, et al,. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-618.
-
(2012)
Gastroenterology
, vol.143
, pp. 608-618
-
-
Poordad, F.1
Bronowicki, J.P.2
Gordon, S.C.3
-
16
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
-
17
-
-
28244461263
-
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase
-
Kukolj G, McGibbon GA, McKercher G, et al,. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005; 280: 39260-39267.
-
(2005)
J Biol Chem
, vol.280
, pp. 39260-39267
-
-
Kukolj, G.1
McGibbon, G.A.2
McKercher, G.3
-
18
-
-
84866315985
-
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir
-
Pelosi LA, Voss S, Liu M, Gao M, Lemm JA,. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012; 56: 5230-5239.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 5230-5239
-
-
Pelosi, L.A.1
Voss, S.2
Liu, M.3
Gao, M.4
Lemm, J.A.5
-
19
-
-
84890973133
-
Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C
-
Bronowicki JP, Pol S, Thuluvath PJ, et al,. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013; 18: 885-893.
-
(2013)
Antivir Ther
, vol.18
, pp. 885-893
-
-
Bronowicki, J.P.1
Pol, S.2
Thuluvath, P.J.3
-
20
-
-
84892761609
-
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
-
Everson GT, Sims KD, Rodriguez-Torres M, et al,. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-429.
-
(2014)
Gastroenterology
, vol.146
, pp. 420-429
-
-
Everson, G.T.1
Sims, K.D.2
Rodriguez-Torres, M.3
-
21
-
-
84904508283
-
Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection
-
November 1-5, 2013: Washington, DC [abstractLB-1]
-
Everson GT, Sims KD, Thuluvath PJ, et al,. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases. November 1-5, 2013: Washington, DC [abstractLB-1].
-
64th Annual Meeting of the American Association for the Study of Liver Diseases
-
-
Everson, G.T.1
Sims, K.D.2
Thuluvath, P.J.3
|